|Day Low/High||2.07 / 2.16|
|52 Wk Low/High||3.61 / 11.14|
What is most fascinating in this index-investing based world is the amount of variability and inefficiency that still exists.
It's been fun to watch some of the stocks that got beaten up badly in 2018 show some signs of life early in the New Year.
This fear and volatility, if it continues, will make tax-loss selling season even more interesting.
These 'Bearish Bets' are showing both technical and quantitative deterioration.
I'll be rolling out next year's candidates in early December.
These 3 value names reported very ugly quarterly earnings.
Nobody caters to both the couch potato as well as the pursuit of the experiential lifestyle better than Walt Disney.
While more than 80 stocks made the cut, I honed the list down to six.
From its present bargain-priced starting point, DF is suitable as both a trading vehicle and a long term investment.
Still, some of these might have the ability to bounce in the New Year, once tax-loss selling is done.
These names are showing technical characteristics of either bullish or bearish reversal patterns.
If the January Effect takes hold with DF there's an opportunity here for attractive returns.
Disney seeks to preserve its content for the expected launch of its own streaming service.
Investors should start looking at dairy companies as butter prices hit new highs.
Stocks pare losses to end mixed with the Dow Jones Industrial Average slightly higher and the S&P 500 and Nasdaq lower.
The rewards of this strategy more than justify the risks.
The direct-to-store distributor could be at risk of falling prey to global food deflation.
U.S. stocks pulled lower as a selloff in health care soured the jobs-inspired rally that pushed benchmark indices to record highs last week.
After his recent investment problems, the pro golfer should stick with what he knows.
The golf company recently put up its best bottom-line in years.
Pro-golfer Phil Mickelson listed as relief defendant in SEC insider trading case and Businessweek shows the money-trail between big pharma and charities.